{"id":"midazolam-hci","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Amnesia"}]},"_chembl":{"chemblId":"CHEMBL655","moleculeType":"Small molecule","molecularWeight":"325.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midazolam binds to GABA-A receptors and potentiates the action of the inhibitory neurotransmitter GABA, increasing chloride ion influx and hyperpolarizing neuronal membranes. This results in depression of central nervous system activity, making it useful for sedation, anxiety relief, and preoperative anxiolysis. The drug has a rapid onset and short duration of action due to its high lipophilicity and rapid redistribution.","oneSentence":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:57.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Preoperative sedation and anxiolysis"},{"name":"Induction of general anesthesia"},{"name":"Acute seizure management"},{"name":"Procedural sedation"}]},"trialDetails":[{"nctId":"NCT03600883","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2018-08-27","conditions":"KRAS p.G12C Mutant Advanced Solid Tumors","enrollment":713},{"nctId":"NCT00261599","phase":"PHASE3","title":"An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-03","conditions":"Conscious Sedation","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR"},{"count":1,"reaction":"EXTRA DOSE ADMINISTERED"},{"count":1,"reaction":"PHARMACEUTICAL PRODUCT COMPLAINT"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Midazolam HCI","genericName":"Midazolam HCI","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation. Used for Preoperative sedation and anxiolysis, Induction of general anesthesia, Acute seizure management.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}